Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E A Peña

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Lifetime Data Analysis|January 1, 1995
Dynamic reliability models with conditional proportional hazardsM Hollander, E A Peña
Lifetime Data Analysis|October 27, 2001
Goodness-of-fit of the distribution of time-to-first-occurrence in recurrent event modelsM Z Agustin, E A Peña
Journal of Dairy Science|January 30, 2002
Antioxidative activity of whey protein hydrolysates in a liposomal systemE A Peña-Ramos, Y L Xiong
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION TrialMarcia S Brose, Martin Schlumbeger, Michael Jeffers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinomaJosep M Llovet, Carol E A Peña, Chetan D Lathia, et al.
Journal of Animal Science|June 27, 2015
Feedlot performance and carcass traits of hairbreed ewe lambs in response to zilpaterol hydrochloride and soybean oil supplementationJ L Dávila-Ramírez, U Macías-Cruz, N G Torrentera-Olivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2016
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH TrialAndrew X Zhu, Yoon-Koo Kang, Olivier Rosmorduc, et al.
Clinical and Translational Science|March 29, 2019
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerJoachim Grevel, Garrit Jentsch, Rupert Austin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Lifetime Data Analysis|January 1, 1995
Dynamic reliability models with conditional proportional hazardsM Hollander, E A Peña
Lifetime Data Analysis|October 27, 2001
Goodness-of-fit of the distribution of time-to-first-occurrence in recurrent event modelsM Z Agustin, E A Peña
Journal of Dairy Science|January 30, 2002
Antioxidative activity of whey protein hydrolysates in a liposomal systemE A Peña-Ramos, Y L Xiong
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION TrialMarcia S Brose, Martin Schlumbeger, Michael Jeffers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinomaJosep M Llovet, Carol E A Peña, Chetan D Lathia, et al.
Journal of Animal Science|June 27, 2015
Feedlot performance and carcass traits of hairbreed ewe lambs in response to zilpaterol hydrochloride and soybean oil supplementationJ L Dávila-Ramírez, U Macías-Cruz, N G Torrentera-Olivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2016
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH TrialAndrew X Zhu, Yoon-Koo Kang, Olivier Rosmorduc, et al.
Clinical and Translational Science|March 29, 2019
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerJoachim Grevel, Garrit Jentsch, Rupert Austin, et al.
Pageof 1